The Hindu Business Line : Novavax ties up with Ranbaxy

NOVAVAX Inc, a specialty biopharmaceutical company has entered into an agreement with Ranbaxy Laboratories to evaluate a new transdermal product. This product has been formulated using Novavax's proprietary micellar nanoparticle (MNP) technology.

In a statement, Mr Nelson M. Sims, President and CEO, Novavax Inc, said: "This agreement demonstrates the merits of our MNP technology to other companies as a value-added proprietary delivery technology for novel drug candidates. This is an example of the commercial and development opportunities micellar nanoparticle technology offers Novavax and our partners."

While the company did not divulge terms of the agreement, it said that Ranbaxy's payment to Novavax includes funding to complete a proof of concept study. Upon successful completion of the proof of concept study, the companies expect to enter into a broad commercialisation and development agreement.

Novavax's micellar nanoparticle technology involves the use of patented oil and water nanoemulsions that allow the topical delivery of drugs. This has been used in Estrasorb, marketed as a topical emulsion that delivers estrogen in a lotion-like formulation used by post-menopausal women.

The company sells, markets, and distributes a line of women's health prescription pharmaceuticals through its specialty sales force calling on obstetricians and gynaecologists throughout the United States. It also conducts research and development on preventative and therapeutic vaccines and proteins for a variety of infectious diseases, including HIV, influenza and SARS.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Leyland buses for Muzaffarabad service

EID Parry Board approves stock split

Divi's Labs hikes FII holdings limit

Ministry to examine Malco's share valuation plan for buyback

Malco delisting: Physical shares now hold the key

Meet on accounting norms at Ujire

Moody's ranks Tata Steel on par with global majors

UB to buy 54 pc stake in Shaw Wallace for Rs 1,300 cr

Jumbo set to exit India

ONGC revives plan to expand MRPL capacity

Ministry to examine shareholding plan of Tata-Murdoch's DTH

M&M, Renault ink pact to produce Logan cars

Novavax ties up with Ranbaxy

GAIL to undertake pipeline projects in Bangladesh

`India cannot be competitor to China'

ONGC mulls agency model for retail outlets

Toyota may go slow on low-end Innova

Arvind Pande made Additional Director of Era Constructions